Medpace Holdings, Inc. (MEDP)
| Market Cap | 5.95B |
| Revenue (ttm) | 955.01M |
| Net Income (ttm) | 159.74M |
| Shares Out | 35.75M |
| EPS (ttm) | 4.22 |
| PE Ratio | 39.14 |
| Forward PE | 37.88 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $165.28 |
| Previous Close | $163.91 |
| Change ($) | 1.37 |
| Change (%) | 0.84% |
| Day's Open | 164.18 |
| Day's Range | 163.27 - 166.61 |
| Day's Volume | 162,396 |
| 52-Week Range | 78.46 - 196.12 |
Medpace (MEDP) delivered earnings and revenue surprises of 15.84% and -1.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Financial Results Revenue ...
Medical stocks Medpace Holdings and Charles River Laboratories were making inroads toward profit-taking zones on Friday as Align Technology flirted with a breakout out of a cup base. The post Three Scor...
Medpace is in a potential buy range with its next earnings report scheduled for Apr. 26. The medical stock is about 3% above a 177.22 buy point from a second-stage.
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace is near a buy zone with earnings due on or around Apr. 26. The post Top-Rated Medpace Near Buy Zone With Earnings Due appeared first on Investor's Business Daily.
The stock of Medpace Holdings (NAS:MEDP, 30-year Financials) shows every sign of being significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the f...
Medpace (MEDP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...
Nasdaq Recovers But Still Faces Key Test; Airbnb, Tencent Music, Medpace Set Up
Nasdaq recovers but still faces key test; Airbnb, Tencent Music, Medpace set up. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing da...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2021 financial results after the market close on Monday, April 26, 20...
And a look at other questions investors might have.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter and Full Yea...
Medpace Hldgs (NASDAQ:MEDP) releases its next round of earnings this Monday, February 15. Here is Benzinga's essential guide to Medpace Hldgs's Q4 earnings report.
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What do they know, and how? By a community of over 100,000 worldwide employee information gatherers reporting back to Market-Maker HQ trading desks. Based on traders' hedges of short positions required ...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its fourth quarter and fiscal year 2020 financial results after the market close on Mon...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference: Credit Suisse Healthcare Conference Date: Tuesda...
Medpace Holdings' (MEDP) CEO August Troendle on Q3 2020 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of 4.63% and 2.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Medpace Hldgs (NASDAQ:MEDP) moved lower by 1% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 53.52% year over year to $1.09, whic...
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Financial Results Reve...
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2020 financial results after the market close on Monday, October 26, ...
Top Ranked Momentum Stocks to Buy for August 28th
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will present at the following investor conference in September: Baird's Global Healthcare Conferenc...
Top Ranked Momentum Stocks to Buy for August 26th
Top Ranked Momentum Stocks to Buy for August 24th
Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for August 20th
The service sector index read 58.1% in July, a 17-month high. Lest we forget, a reading above 48.5% indicates expansion of the broader economy.
Debt is something that gives you the chills since it brings with it the burden of repayment with additional interest in the future. So investors should choose stocks prudently
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q2 2020 Results - Earnings Call Transcript
The clinical trial company's second-quarter financial results were better than expected.
Medpace Holdings stock soared Tuesday to a record high after the provider of clinical testing and research services for drugmakers late Monday forecast better-than-expected revenue for 2020. The post Me...
Medpace (MEDP) delivered earnings and revenue surprises of 61.90% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) delivered earnings and revenue surprises of 52.38% and 13.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace stock jumped in after-hours trading Monday, after rising in the regular session, as second-quarter revenue and full-year revenue guidance handily beat Wall Street expectations.
Shares of Medpace Hldgs (NASDAQ:MEDP) moved higher by 15.7% in after-market trading after the company reported Q2 results.
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2020.
Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medpace Holdings' (MEDP) CEO August Troendle on Q1 2020 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of -1.30% and 1.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medpace Holdings, Inc. (MEDP) CEO August Troendle on Q4 2019 Results - Earnings Call Transcript
Medpace (MEDP) delivered earnings and revenue surprises of 13.33% and 3.51%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Stock Is Up Over 100% In 14 Months, Yet The Sentiment Is Still Bearish On Medpace Holdings
Medpace (MEDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About MEDP
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmac... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 11, 2016 |
| CEO August Troendle | Employees 3,900 |
| Stock Exchange NASDAQ | Ticker Symbol MEDP |
Financial Performance
In 2020, MEDP's revenue was $925.93 million, an increase of 7.54% compared to the previous year's $860.97 million. Earnings were $145.38 million, an increase of 44.74%.
Analyst Forecasts
According to 6 analysts, the average rating for MEDP stock is "Buy." The 12-month stock price forecast is 180.25, which is an increase of 9.06% from the latest price.